Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application
28/08/2026 09:10
BRIEF-Elicera Receives Notice Of Allowance For U.S. Patent Application Aug 28 (Reuters) - Elicera Therapeutics AB ELIC.ST:
PATENT APPLICATION PROTECTS ANTIBODIES TARGETING IL-13RA2 FOR CANCER TREATMENT INCLUDING CAR-T CELL THERAPIES
Source text: ID:nWkr5L155
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application